Archives

  • 2019-07
  • 2019-08
  • 2019-09
  • 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • Meyers CA Albitar M Estey E Cognitive impairment fatigue

    2020-07-04

    [16] Meyers CA, Albitar M, Estey E. Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 2005;104(4):788–93. [17] El-Gohary GM, Azzam HM, Ahmed OI, El-Shokry MH. Pro-inflammatory cytokines and depression in patients with acute leukemia. Egypt J Immunol 2008;15(1): 13–24.
    [18] Panju AH, Danesh A, Minden MD, Kelvin DJ, Alibhai SMH. Associations between quality of life, fatigue, and cytokine levels in patients aged 50+ with acute myeloid leukemia. Support Care Cancer 2009;17(5):539–46.
    [19] Fung FY, Li M, Breunis H, Timilshina N, Minden MD, Alibhai SM. Correlation between cytokine levels and changes in fatigue and quality of life in patients with acute my-eloid leukemia. Leuk Res 2013;37(3):274–9.
    Please cite this article as: S.M.H. Alibhai, H. Breunis, J. Matelski, et al., Age-related cytokine effects on cancer-related fatigue and quality of life in acute myeloid leukemia, J Geriatr Oncol, https://doi.org/10.1016/j.jgo.2019.04.009
    [20] Lacourt TE, Kavelaars A, Galloway-Pena JR, Sahasrabhojane PV, Shah ND, Futreal A, et al. Associations of Hexa His tag peptide with symptom burden in patients with acute my-eloid leukemia. Psychoneuroendocrinology 2018;89:203–8. [21] Barsevick A, Frost M, Zwinderman A, Hall P, Halyard M. I'm so tired: biological and genetic mechanisms of cancer-related fatigue. Qual Life Res 2010;19(10): 1419–27.
    [22] Miller AH, Ancoli-Israel S, Bower JE, Capuron L, Irwin MR. Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer. J Clin Oncol 2008; 26(6):971–82.
    [23] Wang XS, Shi Q, Shah ND, Heijnen CJ, Cohen EN, Reuben JM, et al. Inflammatory markers and development of symptom burden in patients with multiple myeloma during autologous stem cell transplantation. Clin Cancer Res 2014;20(5):1366–74. [24] Wang XS, Williams LA, Krishnan S, Liao Z, Liu P, Mao L, et al. Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun 2012;26(5):699–705.
    [25] Monk JP, Phillips G, Waite R, Kuhn J, Schaaf LJ, Otterson GA, et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients. J Clin Oncol 2006;24(12):1852–9.
    [29] Alibhai SMH, Breunis H, Timilshina N, Brignardello-Petersen R, Tomlinson G, Mohamedali H, et al. Quality of life and physical function in adults treated with in-tensive chemotherapy for acute myeloid leukemia improve over time independent of age. J Geriatr Oncol 2015;6(4):262–71.
    [30] Mohamedali H, Breunis H, Timilshina N, Brandwein JM, Gupta V, Li M, et al. Older age is Abundant mRNA associated with similar quality of life and physical function compared to youn-ger age during intensive chemotherapy for acute myeloid leukemia. Leuk Res 2012; 36(10):1241–8.
    [31] Grimwade D, Walker H, Harrison G, Oliver F, Chatters S, Harrison CJ, et al. The pre-dictive value of hierarchical cytogenetic classification in older adults with acute my-eloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001;98(5):1312–20. [32] Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, et al. Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid Leukemia. J Clin Oncol 2003;21(24):4642–9.
    [33] Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prog-nostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40(5):373–83. [34] Cella D. The functional assessment of Cancer therapy-Anemia (FACT-an) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997;34(3 Suppl 2):13–9.
    [35] Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the functional assessment of Cancer therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage 2002;24(6):547–61.
    [36] Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85(5):365–76.
    [38] Greenberg DB, Gray JL, Mannix CM, Eisenthal S, Carey M. Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for pros-tate cancer. J Pain Symptom Manage 1993;8(4):196–200.
    [40] Bower JE, Ganz PA, Aziz N, Fahey JL. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002;64(4):604–11.